MarketPeel
Insider Trading Intelligence
HR

H. Lawrence Remmel

ATOS
DIRECTOR · ATOSSA THERAPEUTICS, INC. · CIK 0001551817
FILING MIX · LIFETIME100%/0%
BUYS
8
SELLS
0
TOTAL VALUE
$7.0K
COMPANIES
1
ACTIVE SINCE
May 2020
HOLDINGS NOW
10,683
AVG SELL PX
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by H. Lawrence Remmel, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-1.25%-0.72%-0.53%-0.53%
14d1+0.00%-10.96%-3.51%-7.45%-7.45%
30d1+100.00%+9.15%-3.16%+12.30%+12.30%
60d1+100.00%+19.20%+1.85%+17.35%+17.35%
90d1+100.00%+19.20%+6.72%+12.48%+12.48%
180d1+100.00%+19.20%+17.28%+1.92%+1.92%
1y1+0.00%-54.90%+13.45%-68.36%-68.36%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ATOS · 10,683 shares · as of May 12, 2026
031,25062,50093,750125,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 8 buys / 0 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,00010,683May 12, 2026May 14, 2026View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000125,000May 15, 2025May 16, 2025View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
10,000$0.70$7.0K10,257Mar 26, 2025Mar 28, 2025View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000125,000Jun 27, 2024Jul 1, 2024View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000125,000May 4, 2023May 5, 2023View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000May 13, 2022May 16, 2022View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000May 14, 2021May 18, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,00045,000May 15, 2020May 19, 2020View →
Other insiders · ATOS
Loading peer insiders…
About this filer
CIK 0001551817
ROLE
Director
PRIMARY
ATOS
COMPANIES
1
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001551817DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback